Cardiovascular risk stratification in autoimmune diseases in a university hospital
Abstract
Introduction: Autoimmune diseases (AID) have been considered as non-fatal; however, most of these have a natural history of premature mortality. Some such as lupus erythematosus (SLE), rheumatoid arthri-tis (RA), systemic sclerosis (SS), polymyositis, vasculitis and others are associated with early mortality comparable to cardiovascular and neo-plastic diseases.Objectives: 1- Identify autoimmune diseases with increased cardiovas-cular risk in previously diagnosed patients who are treated at a rheuma-tology service of an university hospital. 2- To compare the cardiovascu-lar risk calculated according to the Framingham and the SCORE model in patients with a previous diagnosis of autoimmune disease treated at a rheumatology service of a public hospital. Methods: A cross-sectional analytical study in the rheumatology de-partment of an university hospital was carried out where 129 medical records of patients were recruited. They came spontaneously between November 1, 2010 and May 31, 2011. Tables of combination of vari-ables were carried out and its subsequent calculation with the help of the Chi Square statistical coefficient and Pearson coefficient.Results: The AID with increased cardiovascular risk were RA, vascu-litis and EASN. The Framingham showed a single patient with RA who had very high CVR. The high CVR was led by vasculitis with 16.7%, but it must be stressed that this corresponds to a single patient. The second place was represented by RA (10.7%), then EASN (10%) and SLE (4.5%). The SCORE model showed that 3.1% of the diseases had a very high cardiovascular risk, and this percentage was comprised of 3 patients with RA and 1 with vasculitis. The high CVR was represented only by 13.3% RA. When comparing the two scales of cardiovascular risk, 70.5% of 129 patients had low CVR. Only one patient (0.8%) with low cardiovascular risk in the Framingham had very high CVR in SCORE. According to the correlation coefficient R of Pearson association exists a level of almost 50%, therefore, it was shown that there is good cor-respondence between these variables.Conclusion: We found a positive correlation between the two scales, and diseases with increased cardiovascular risk were RA, vasculitis and EASN, highlighting the low number of cases in the last two compared with RA. Notoriously, the evidence level is higher in RA and SLE than in any other autoimmune disease. This does not rule out that the rest of them carry high CVR. Prospective multi-centre studies should consider for the development of guides the rest of autoimmune diseases or for the implementation of existing ones. This work presents no conflict of interest.References
I. Alba P. Ateroesclerosis acelerada en enfermedades autoinmu-nes. Revista Facultad de Ciencias Médicas 2008; 65 (4):107-108.
II. Wilson P, D´Agostino R, Levy D, Belanger A, Silbershatz H. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837-47.
III. Grundy S, Pasternak R, Greenland P, Smith S Jr, Fuster V. As-sessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American Co-llege of Cardiology. Circulation 1999; 100:1481-92.
IV. Aranceta J, Pérez C, Foz M, Mantilla T, Serra L, Moreno B, et al. Grupo Colaborativo para el estudio DORICA fase II. Tablas de evaluación del riesgo coronario adaptadas a la población es-pañola. Estudio DORICA Med Clin (Barc). 2004; 123:686-91.
V. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, de Backer G, et al, on behalf of the SCORE Project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SOCRE Project. Eur Heart J. 2003; 24:987-1003.
VI. Ian Grahama, Dan Atara, Knut Borch-Johnsenb, Gu-drun Boysend. Guías de práctica clínica sobre prevención de la enfermedad cardiovascular: versión resumida. Rev Esp Cardiol. 2008; 61 (1):e1-e49.
VII. Peters MJL, Symmons DPM, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk ma-nagement in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010; 69:325-331.
VIII. Jeffrey S. Berger, MS, Courtney O. Jordan, MD, Donald Lloyd-Jones, MD. Screening for cardiovascular risk in as-ymptomatic patients. Journal of the American College of Cardiology Vol. 55, No. 12, 2010.
IX. Jaume Marrugata, Pascual Solanas, Ralph D´Agostinod, Lisa Sullivand. Estimación del riesgo coronario en Espa-ña mediante la ecuación de Framingham calibrada. Rev Esp Cardiol. 2003; 56 (3):253-61.
X. Paulino González-Diego, Conchi Moreno-Iribas, María Jesús Guembea. Adaptación de la función de riesgo coro-nario de Framingham-Wilson para la población de Navarra (RICORNA). Rev Esp Cardiol. 2009; 62 (8):875-85.
XI. Brotons C, Cascant P, Ribera A, Moral I, Permanyer G. Utilidad de la medición del riesgo coronario a partir de casos y controles. Med Clin (Barc). 2003; 121:327-30.
XII. García-Ortiz L, Gómez-Marcos MA, González-Elena LJ, Rodríguez-Sánchez E, García García Á. Framingham-Grundy, REGICOR y SCORE en la esti-mación del riesgo cardiovascular del paciente hipertenso. Concordancias y discrepancias (CICLO-RISK). Hiper-tensión (Madr). 2006; 23 (4):111-7.
XIII. Avouac J, Allanore Y. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs. Expert Opin Phar-macother. 2008; 9:1121-1128.
XIV. Stephanie O. Keeling & Michelle Teo & Daisy Fung. Lack of cardiovascular risk assessment in inflammatory arthritis and systemic lupus erythematosus patients at a tertiary care center. Clin Rheymatol DOI 10.1007 / s10067-011-1747-9.
XV. Michael T Nurmohamed, George Kitas. Cardiovascular risk in rheumatoid arthritis and diabetes: how does it compare and when does it start? Ann Rheum Dis. June 2011. Vol 70 No 6.
XVI. Murray B. Urowitz, MD; Dafna D. Gladman, MD. The SLICC Inception Cohort for Atherosclerosis. Current Rheumatology Reports. 2008; 10:281-285.
XVII. Meune C, Touzé E, Trinquart L, Allanore Y. Trends in cardiovascular mortality in patients with rheumatoid ar-thritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatol (Oxford) 2009; 48:1309-1313.
XVIII. Rasker JJ and Cosh JA. Cause and age at death in a pros-pective study of 100 patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 1981, 40:115-120.
XIX. Guillermo J. Pons-Estel, Luis A. GonzaIez, Jie Zhang. Predictors of cardiovascular damage in patients with syste-mic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort. Rheumatology 2009; 48:817-822.
XX. Young Hee Rho, MD, PhD, Cecilia P. Chung, MD. Inflammatory mediators and premature coronary athe-rosclerosis in rheumatoid arthritis. Arthritis Rheum. 2009. November 15; 61 (11):1580-1585.
Copyright (c) 2013 Argentine Journal of Rheumatology

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.